| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |